ADMA (ADMA Biologics) Change In Inventory: $-49.9 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ADMA ADMA Biologics Inc ADMA
64 GF Score
Price $8.87
GF Value $18.08
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is ADMA Biologics Change In Inventory?

ADMA Biologics ADMA -1.11% 64 Change In Inventory is $-49.9 Mil as of Mar. 2026. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.08 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ADMA Biologics's change in inventory for the quarter that ended in Mar. 2026 was $-15.6 Mil. It means ADMA Biologics's inventory increased by $15.6 Mil from Dec. 2025 to Mar. 2026 .

ADMA Biologics's change in inventory for the fiscal year that ended in Dec. 2025 was $-36.2 Mil. It means ADMA Biologics's inventory increased by $36.2 Mil from Dec. 2024 to Dec. 2025 .

ADMA Biologics's Total Inventories for the quarter that ended in Mar. 2026 was $222.1 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ADMA Biologics's Days Inventory for the quarter that ended in Mar. 2026 was 579.47.

Inventory Turnover measures how fast the company turns over its inventory within a year. ADMA Biologics's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ADMA Biologics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.87.

ADMA Biologics  (NAS:ADMA) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ADMA Biologics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=214.2815/33.743*365 / 4
=579.47

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

ADMA Biologics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=33.743 / 214.2815
=0.16

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ADMA Biologics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=214.2815 / 114.493
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Change In Inventory Related Terms

ADMA Biologics Change In Inventory Historical Data

* Premium members only.

The historical data trend for ADMA Biologics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics Change In Inventory Chart

ADMA Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -43.19 -38.56 -9.63 2.67 -36.23

ADMA Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.95 -19.28 -5.20 -9.80 -15.63
ADMA
64GF Score
ADMA Biologics Inc ADMA
Change In Inventory is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ADMA Biologics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $-49.9 Mil mean?
ADMA Biologics (ADMA) has a Change In Inventory of $-49.9 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for ADMA Biologics and its competitors.
Is ADMA Biologics' Change In Inventory too high?
ADMA Biologics' current Change In Inventory is $-49.9 Mil. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Change In Inventory compare to ZLAB and HRMY?
ADMA Biologics' Change In Inventory of $-49.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Biotechnology company?
A good Change In Inventory depends on the Biotechnology industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for ADMA Biologics and its competitors. ADMA Biologics's current Change In Inventory is $-49.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.08, compared to a current price of $8.87 — trading 51% below its estimated fair value. The current Change In Inventory is $-49.9 Mil. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Change In Inventory is $-49.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ADMA Biologics (ADMA) Overvalued in 2026?

Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued. The current stock price of $8.87 is trading 51% below its estimated GF Value™ of $18.08. GuruFocus considers ADMA Biologics to be Significantly Undervalued.

Key valuation signals for ADMA:

  • Change In Inventory: $-49.9 Mil
  • GF Value™: $18.08 vs. price of $8.87 (51% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ADMA Biologics Business Description

Address 465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score

Get the complete analysis for ADMA

Change In Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.87
Price
$18.08
GF Value